Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 25, 2026, 2:57 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 361–384 of 2,633 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Intermediate dose Clear all
Withdrawn Phase 2 Interventional Accepts healthy volunteers

CD34+ Enriched Transplants From HLA-Compatible Patients With Hematologic Malignancies

NCT04282174
View directory record Official record
Conditions
Hematologic Diseases, Hematologic Malignancy, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Chronic Myelogenous Leukemia, Chronic Lymphocytic Leukemia
Interventions
CliniMACS, Bone Marrow Transplant, Hyperfractionated Total Body Irradiation, Thiotepa, Cyclophosphamide, Busulfan, Melphalan, Fludarabine
Device · Procedure · Drug
Lead sponsor
Baptist Health South Florida
Other
Eligibility
Up to 74 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2030
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Sep 27, 2022 · Synced Oct 25, 2026, 2:57 AM EDT
No Longer Available No phase listed Expanded access

Riociguat in Patients With Chronic Thromboembolic Pulmonary Hypertension (CTEPH)

NCT01784562
View directory record Official record
Conditions
Hypertension, Pulmonary
Interventions
Adempas (Riociguat, BAY63-2521)
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years to 80 Years
U.S. locations
24
States / cities
Tucson, Arizona • La Jolla, California • Los Angeles, California + 20 more
Source: ClinicalTrials.gov public record
Updated Jan 6, 2016 · Synced Oct 25, 2026, 2:57 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Low vs. Moderate to High Dose Vitamin D for Prevention of COVID-19

NCT04868903
View directory record Official record
Conditions
SARS-CoV-2 Infection
Interventions
Vitamin D3
Dietary Supplement
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
1,475 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2024
U.S. locations
2
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 22, 2026 · Synced Oct 25, 2026, 2:57 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Safety, Tolerability, and PK in Healthy Volunteers and HCV Genotype 1 Infected Patients

NCT01523990
View directory record Official record
Conditions
Healthy, Hepatitis C, Chronic
Interventions
TG-2349, placebo
Drug
Lead sponsor
TaiGen Biotechnology Co., Ltd.
Industry
Eligibility
18 Years to 65 Years
Enrollment
135 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2013
U.S. locations
1
States / cities
Cypress, California
Source: ClinicalTrials.gov public record
Updated Dec 19, 2014 · Synced Oct 25, 2026, 2:57 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Single Dose Bioavailability and Ethnobridging PK Study in Healthy Subjects

NCT04587713
View directory record Official record
Conditions
Intestinal Disorder, Bowel Diseases, Inflammatory
Interventions
TD-1473 [Tablet A], TD-1473 [Tablet B]
Drug
Lead sponsor
Theravance Biopharma
Industry
Eligibility
19 Years to 55 Years
Enrollment
58 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
2
States / cities
Cypress, California • Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Apr 9, 2021 · Synced Oct 25, 2026, 2:57 AM EDT
Terminated Phase 2 Interventional Results available

Allogeneic Stem Cell Transplant for Patients With Severe Aplastic Anemia

NCT00578903
View directory record Official record
Conditions
Aplastic Anemia
Interventions
Cytoxan, Campath, Total Body Irradiation (TBI), FK-506, Methotrexate, Stem cell infusion
Drug · Radiation · Procedure
Lead sponsor
Baylor College of Medicine
Other
Eligibility
1 Minute to 60 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2012
U.S. locations
2
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 22, 2016 · Synced Oct 25, 2026, 2:57 AM EDT
Completed Phase 1 Interventional

Zoledronic Acid (ZOMETA) With Cyclophosphamide With Neuroblastoma and Cortical Bone Involvement

NCT00206388
View directory record Official record
Conditions
NEUROBLASTOMA
Interventions
Zolendric acid, Cyclophosphamide
Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
Up to 30 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2013
U.S. locations
8
States / cities
Los Angeles, California • San Francisco, California • Stanford, California + 5 more
Source: ClinicalTrials.gov public record
Updated Aug 2, 2013 · Synced Oct 25, 2026, 2:57 AM EDT
Completed Phase 2 Interventional Results available

Cyclophosphamide for Hematopoietic Stem Cell Mobilization in Patients With a Hematologic Malignancy

NCT02139280
View directory record Official record
Conditions
Hematologic Malignancies
Interventions
Cyclophosphamide
Drug
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years and older
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2020
U.S. locations
1
States / cities
Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated Feb 16, 2021 · Synced Oct 25, 2026, 2:57 AM EDT
Suspended Early Phase 1 Interventional

Using Aspirin to Improve Immunological Features of Ovarian Tumors

NCT05080946
View directory record Official record
Conditions
Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer
Interventions
Aspirin 325mg, Placebo
Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older · Female only
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
4
States / cities
Tampa, Florida • Portland, Oregon • Charlottesville, Virginia + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 15, 2026 · Synced Oct 25, 2026, 2:57 AM EDT
Completed Phase 3 Interventional Results available

Cannabidiol Oral Solution as an Adjunctive Treatment for Treatment-resistant Seizure Disorder

NCT02318602
View directory record Official record
Conditions
Seizures
Interventions
Cannabidiol Oral Solution
Drug
Lead sponsor
INSYS Therapeutics Inc
Industry
Eligibility
1 Year to 18 Years
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
11
States / cities
San Francisco, California • Miami, Florida • Pensacola, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Jul 26, 2018 · Synced Oct 25, 2026, 2:57 AM EDT
Terminated Phase 2 Interventional Results available

Drug-Drug Interactions Between Rifapentine and Dolutegravir in HIV/LTBI Co-Infected Individuals

NCT04272242
View directory record Official record
Conditions
HIV Infection, LTBI
Interventions
Dolutegravir (DTG), Isoniazid (INH), Rifapentine (RPT), Antiretroviral Therapy (ART), Pyridoxine (Vitamin B6)
Drug · Dietary Supplement
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 65 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
2
States / cities
San Francisco, California • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 19, 2024 · Synced Oct 25, 2026, 2:57 AM EDT
Recruiting Phase 2 Interventional

The Cardiovascular Consequences of Sleep Apnea Plus COPD (Overlap Syndrome)

NCT05237505
View directory record Official record
Conditions
Obstructive Sleep Apnea, Chronic Obstructive Pulmonary Disease, Overlap Syndrome
Interventions
bi-level positive pressure non invasive ventilation, Oxygen gas
Device · Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
40 Years to 79 Years
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Jun 3, 2026 · Synced Oct 25, 2026, 2:57 AM EDT
Terminated Phase 2 Interventional

Long-term Study of AIR001 in Subjects With WHO Group 1 Pulmonary Arterial Hypertension Who Completed AIR001-CS05

NCT01725269
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
AIR001
Drug
Lead sponsor
Aires Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
17
States / cities
La Jolla, California • Torrance, California • Aurora, Colorado + 12 more
Source: ClinicalTrials.gov public record
Updated Apr 9, 2014 · Synced Oct 25, 2026, 2:57 AM EDT
Recruiting Phase 3 Interventional

A Study to Evaluate the Efficacy and Safety of Esketamine for Reduction of Symptoms of Major Depressive Disorder

NCT07227454
View directory record Official record
Conditions
Depressive Disorder, Major
Interventions
Esketamine, Midazolam, Oral Placebo, Intranasal Placebo
Drug · Other
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
12 Years to 17 Years
Enrollment
258 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
10
States / cities
Birmingham, Alabama • Washington D.C., District of Columbia • Atlanta, Georgia + 7 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 25, 2026, 2:57 AM EDT
Terminated Phase 3 Interventional Results available

Rituximab or Zevalin - Efficacy Trial of Therapeutic Alternatives (RoZetta)

NCT01662102
View directory record Official record
Conditions
Follicular Lymphoma
Interventions
Zevalin, Rituximab
Drug
Lead sponsor
Spectrum Pharmaceuticals, Inc
Industry
Eligibility
18 Years to 75 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
5
States / cities
Sun City, Arizona • Athens, Georgia • Niles, Illinois + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 4, 2021 · Synced Oct 25, 2026, 2:57 AM EDT
Not yet recruiting Not applicable Interventional

Dynamic, Real-world Learning, Innovative Mobility, and Versatile Exploration (DRIVE): Evaluating a Dose-matched Developmental Powered Mobility Intervention for Young Children With Cerebral Palsy

NCT07876219
View directory record Official record
Conditions
Cerebral Palsy
Interventions
Permobil Explorer Mini, MORE-PT
Device · Other
Lead sponsor
University of Washington
Other
Eligibility
12 Months to 33 Months
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2030
U.S. locations
2
States / cities
Grand Rapids, Michigan • Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Oct 15, 2026 · Synced Oct 25, 2026, 2:57 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

TIV and High Dose TIV in Subjects With Rheumatoid Arthritis

NCT01436370
View directory record Official record
Conditions
Influenza
Interventions
Trivalent inactivated influenza vaccine
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 64 Years
Enrollment
102 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2013
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Dec 24, 2014 · Synced Oct 25, 2026, 2:57 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Safety and Efficacy Study of NatrOVA Creme Rinse - 1% and NIX Creme Rinse in Subjects 6 Months or Older With Head Lice

NCT00545753
View directory record Official record
Conditions
Pediculosis
Interventions
Spinosad, Permethrin 1%
Drug
Lead sponsor
ParaPRO LLC
Industry
Eligibility
6 Months and older
Enrollment
558 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
6
States / cities
Scottsdale, Arizona • Hot Springs, Arkansas • Beverly Hills, California + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 11, 2012 · Synced Oct 25, 2026, 2:57 AM EDT
Completed Phase 1 Interventional

Cabozantinib in Combination With 13-cis-Retinoic Acid in Children With Relapsed or Refractory Solid Tumors

NCT03611595
View directory record Official record
Conditions
Solid Tumor
Interventions
Cabozantinib, 13-cis-retinoic acid
Drug
Lead sponsor
Peter Zage
Other
Eligibility
2 Years to 26 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
2
States / cities
San Diego, California • Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated May 27, 2026 · Synced Oct 25, 2026, 2:57 AM EDT
Completed Phase 2 Interventional

Abatacept Conversion in Kidney Transplantation

NCT04955366
View directory record Official record
Conditions
Renal Transplant Recipient
Interventions
Belatacept, Abatacept
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Sep 16, 2026 · Synced Oct 25, 2026, 2:57 AM EDT
Completed Phase 2 Interventional Results available

Steroid Dosing by bioMARker Guided Titration in Critically Ill Patients With Pneumonia

NCT03852537
View directory record Official record
Conditions
Pneumonia
Interventions
Methylprednisolone, Usual Care
Drug · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 16, 2021 · Synced Oct 25, 2026, 2:57 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Drug-drug Interaction Study of Gepotidacin

NCT04493931
View directory record Official record
Conditions
Infections, Bacterial
Interventions
Gepotidacin, Cimetidine, Rifampicin, Midazolam, Digoxin, Placebo matching to gepotidacin
Drug · Other
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 50 Years
Enrollment
64 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
Las Vegas, Nevada
Source: ClinicalTrials.gov public record
Updated Mar 4, 2022 · Synced Oct 25, 2026, 2:57 AM EDT
Terminated Phase 2 Interventional Results available

SCD-Haplo: Phase II Study of HLA-Haploidentical SCT for Aggressive SCD

NCT02013375
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
Haploidentical Transplant, Alemtuzumab, Total Body Irradiation, Cyclophosphamide, Sirolimus
Procedure · Drug · Radiation
Lead sponsor
Damiano Rondelli, MD
Other
Eligibility
16 Years to 60 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 28, 2019 · Synced Oct 25, 2026, 2:57 AM EDT
Completed Phase 1 Interventional

AMG 595 First-in-Human in Recurrent Gliomas

NCT01475006
View directory record Official record
Conditions
Advanced Malignant Glioma, Anaplastic Astrocytomas, Glioblastoma Multiforme
Interventions
AMG 595
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
3
States / cities
Los Angeles, California • Boston, Massachusetts • Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 15, 2016 · Synced Oct 25, 2026, 2:57 AM EDT